1 WHO consolidated guidelines on tuberculosis. Module 4: Treatment. Drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020.

2 Guidelines for treatment of drug-susceptible tuberculosis and patient care (2017 update). Geneva: World Health Organization; 2017 (, accessed 1 June 2020).

3 WHO consolidated guideline on tuberculosis. Module 1: Prevention – tuberculosis preventive treatment. Geneva: World Health Organization; 2020.

4 WHO handbook for guideline development – 2nd edition. Geneva, Switzerland: World Health Organization; 2014 (, accessed 20 March 2020).

5 Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis (WHO/HTM/TB/2014.11). Geneva: World Health Organization; 2014 ( iris/bitstream/handle/10665/130918/9789241548809_eng.pdf?sequence=1, accessed 20 March 2020).

6 Implementing tuberculosis diagnostics: a policy framework. Geneva: World Health Organization; 2015 (, accessed 1 June 2020).

7 Wiseman CA, Gie RP, Starke JR, Schaaf HS, Donald PR, Cotton MF et al. A proposed comprehensive classification of tuberculosis disease severity in children. Pediatr Infect Dis J. 2012;31(4):347–52.

8 WHO best-practice statement on the off-label use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis. Geneva: World Health Organization; 2017 ( handle/10665/258941, accessed 1 June 2020).

9 Allotey P, Reidpath DD, Ghalib H, Pagnoni F, Skelly WC. Efficacious, effective, and embedded interventions: implementation research in infectious disease control. BMC Public Health. 2008;8(1):343.

10 The Global Fund, World Health Organization. Guide to operational research in programs supported by the Global Fund. Geneva: The Global Fund; 2007 (, accessed 1 June 2020).

11 Expanding capacity for operations research in reproductive health: summary report of a consultative meeting: WHO, Geneva, Switzerland, December 10–12, 2001. Geneva: World Health Organization; 2003 (, accessed 1 June 2020).

12 Weyer K, Mirzayev F, Migliori GB, van Gemert W, D’Ambrosio L, Zignol M et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J. 2013;42(1):252–71.

13 The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance [WHO/HTM/TB/2016.07]. Geneva: World Health Organization; 2016 ( iris/bitstream/handle/10665/246131/9789241510561-eng.pdf?sequence=1, accessed 20 March 2020).

14 Guidelines for surveillance of drug resistance in tuberculosis. 5th edition. Geneva: World Health Organization; 2015 (, accessed 1 June 2020).

15 WHO treatment guidelines for drug-resistant tuberculosis, 2016 update (WHO/HTM/TB/2016.04). Geneva: World Health Organization; 2016 ( eng.pdf, accessed 20 March 2020).

16 Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis. Geneva: World Health Organization; 2018 ( susceptibility_testing/en/, accessed 1 June 2020).

17 Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB. Geneva: World Health Organization; 2018 ( WHO_technical_report_concentrations_TB_drug_susceptibility/en/, accessed 20 March 2020).

18 Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81.

19 Active tuberculosis drug-safety monitoring and management (aDSM): framework for implementation. Geneva: World Health Organization; 2015 (, accessed 1 June 2020).

20 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Genevva: World Health Organization; 2016 (;jsessionid=2FD2A34B73DE76 E3C987F452664F8BAC?sequence=1, accessed 6 June 2020).

21 Ramachandran G, Kumar AH, Srinivasan R, Geetharani A, Sugirda P, Nandhakumar B et al. Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin. Indian J Med Res. 2012;136(6):979.

22 Baniasadi S, Eftekhari P, Tabarsi P, Fahimi F, Raoufy MR, Masjedi MR et al. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. European J Gastroent Hepatol. 2010;22(10):1235–8.

23 van Hest R, Baars H, Kik S, van Gerven P, Trompenaars M-C, Kalisvaart N et al. Hepatotoxicity of rifampinpyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis. 2004;39(4):488–96.

24 Peloquin CA, Jaresko GS, Yong C-L, Keung A, Bulpitt AE, Jelliffe RW. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemoth. 1997;41(12):2670–9.

25 Global Drug Facility – Procurement and supply – List of products avaialble [website]. Stop TB Partnership; (, accessed 6 June 2020 2020).

26 Definitions and reporting framework for tuberculosis – 2013 revision (updated December 2014) [WHO/ HTM/TB/2013.2]. Geneva, Switzerland: World Health Organization; 2013 ( handle/10665/79199/9789241505345_eng.pdf?sequence=1, accessed 20 March 2020).

27 GRADE working group [website]. (, accessed 6 June 2020).

28 Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9(8):e1001300.

29 Public call for individual patient data on treatment of rifampicin and multidrug-resistant (MDR/RR-TB) tuberculosis. Geneva: World Health Organization; 2018 ( call_treatment_RR_MDR_TB/en/, accessed 27 February 2018).

30 Public call for individual patient data on treatment of rifampicin and multidrug-resistant (MDR/RR-TB) tuberculosis. Geneva: World Health Organization; 2019 (, accessed 10 April 2020).

31 Tanke ED, Leirer VO. Automated telephone reminders in tuberculosis care. Med Care. 1994;32(4):380–9.

32 Highlights of prescribing information Sirturo Maryland, United States of America: United States Food and Drug Administration; 2020. Maryland: United States Food and Drug Administration (FDA); 2020 (https://, accessed 1 June 2020).

33 Van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684–92.

34 Hartkoorn R, Uplekar S, Cole S. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58(5):2979–81 (https://, accessed 1 June 2020).

35 Svensson EM, Yngman G, Denti P, McIlleron H, Kjellsson MC, Karlsson MO. Evidence-based design of fixeddose combinations: principles and application to pediatric anti-tuberculosis therapy. Clin Pharmacokinet. 2018;57(5):591–9.

36 ShORRT (Short, all-Oral Regimens For Rifampicin-resistant Tuberculosis) Research Package. Geneva: World Health Organization and the Special Programme for Research and Training in Tropical Diseases; 2015 (, accessed 1 June 2020).

37 Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE handbook. Hamilton, Canada:2013 (https://gdt., accessed 1 June 2020).

38 Guidelines for the programmatic management of drug-resistant tuberculosis, 2011 update (WHO/HTM/ TB/2011.6). Geneva, Switzerland: World Health Organization; 2011 ( drug-resistant-tb/programmatic_guidelines_for_mdrtb/en/, accessed 02 March 2017).

39 WHO treatment guidelines for isoniazid-resistant tuberculosis. Supplement to the WHO treatment guidelines for drug-resistant tuberculosis (WHO/CDS/TB/2018.7). Geneva: World Health Organization; 2018 (https://, accessed 20 March 2020).

40 Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. New Eng J Med. 2006;354(13):1352–61 ( NEJMoa055191, accessed 14 May 2013).

41 European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. 2019 ( human/referrals/quinolone-fluoroquinolone-containing-medicinal-products, accessed 08 April 2019).

42 FDA drug safety communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects [website]. Maryland: US Food and Drug Administration (FDA); 2018 (https://, accessed 8 April 2020).

43 Sirturo™ (bedaquiline 100 mg tablets) for the treatment of adults (≥ 18 years) as part of combination therapy of pulmonary multi-drug resistant tuberculosis (MDRTB) [website]. Maryland, United States of America: US Food and Drug Administration; 2012 (–01- FDA_Backgrounder.pdf, accessed 20 March 2020).

44 The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance [WHO/HTM/TB/2013.6]. Geneva, Switzerland: World Health Organization; 2013 ( challenges/mdr/bedaquiline/en/, accessed 03 March 2017).

45 Schnippel K, Ndjeka N, Maartens G, Meintjes G, Master I, Ismail N et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018;6(9):699–706 (, accessed 03 January 2019).

46 Kim CT, Kim T-O, Shin H-J, Ko YC, Hun Choe Y, Kim H-R et al. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea. Eur Respir J. 2018;51(3):1702467 (, accessed 11 June 2018).

47 Pontali E, Sotgiu G, Tiberi S, D’Ambrosio L, Centis R, Migliori GB. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J. 2017;50(5):1801386 ( pubmed/29146605, accessed 10 April 2020).

48 Guglielmetti L, Jaspard M, Le Dû D, Lachâtre M, Marigot-Outtandy D, Bernard C et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3):1601799 (, accessed 11 June 2018).

49 Dooley KE, Rosenkranz S, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F et al.; on behalf of the AIDS Clinical Trials Group A5343 Study Team. QT effects of bedaquiline, delamanid or both in MDR-TB patients: the DELIBERATE trial (DELamanId BEdaquiline for ResistAnt TubErculosis). Conference on Retroviruses and Opportunistic Infections (CROI). Seattle, Washington, United States of America. 4–7 March 2019.

50 Olayanju O EA, Limberis J, Dheda K. A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis. Eur Respir J. 2020;55(1901181 ).

51 Evaluating the safety, tolerability, and pharmacokinetics of bedaquiline and delamanid, alone and in combination, for drug-resistant pulmonary tuberculosis [website]. US National Library of Medicine; (https://, accessed 1 June 2020).

52 Drug interactions [website]. Indiana, USA: Indiana University School of Medicine; (http://medicine.iupui. edu/clinpharm/ddis/, accessed 1 June 2020).

53 endTB clinical and programmatic guide for patient management with new TB drugs. Version 4.0. endTB Consortium; 2018.

54 HIV drug interactions [website]. Liverpool, United Kingdom: University of Liverpool; 2020 (, accessed 11 March 2020).

55 Brüggemann RJ, Alffenaar J-WC, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48(10):1441–58.

56 Tang S, Yao L, Hao X, Zhang X, Liu G, Liu X et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China. Eur Respir J. 2015;45(1):161–70.

57 Im JH, Baek JH, Kwon HY, Lee J-S. Incidence and risk factors of linezolid-induced lactic acidosis. Int J Infect Dis. 2015;31:47–52 (, accessed 03 January 2019).

58 Lee M, Lee J, Carroll MW, Choi H, Min S, Song T et al. Linezolid for treatment of chronic extensively drugresistant tuberculosis. New Eng J Med. 2012;367(16):1508–18 ( NEJMoa1201964, accessed 20 November 2012).

59 Mao Y, Dai D, Jin H, Wang Y. The risk factors of linezolid-induced lactic acidosis: a case report and review. Med. 2018;97(36):e12114 (–201809070–00037, accessed 03 January 2019).

60 Technical report on the pharmacokinetics and pharmacodynamics (PK/PD) of medicines used in the treatment of drug-resistant tuberculosis. Geneva: World Health Organization; 2018 ( iris/handle/10665/260440, accessed 1 June 2020).

61 Diacon AH, De Jager VR, Dawson R, Narunsky K, Vanker N, Burger DA et al. Fourteen-day bactericidal activity, safety, and pharmacokinetics of linezolid in adults with drug-sensitive pulmonary tuberculosis. Antimicrob Agents Chemoth. 2020;64(4).

62 Sotgiu G, Centis R, D’Ambrosio L, Alffenaar J-WC, Anger HA, Caminero JA et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and metaanalysis. Eur Respir J. 2012;40(6):1430–42.

63 Tiberi S, D’Ambrosio L, De Lorenzo S, Viggiani P, Centis R, Sotgiu G et al. Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience. Eur Respir J. 2016;47(1):333–6.

64 Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA. The risk of seizures among the carbapenems: a metaanalysis. J Antimicrob Chemother. 2014;69(8):2043–55 ( doi/10.1093/jac/dku111, accessed 04 January 2019).

65 Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother. 2005;49(7):2816–21 (, accessed 04 December 2018).

66 Dooley KE, Obuku EA, Durakovic N, Belitsky V, Mitnick C, Nuermberger EL et al. World Health Organization Group 5 drugs for the treatment of drug-resistant tuberculosis: Unclear efficacy or untapped potential? J Infect Dis. 2013;207(9):1352–8 (, accessed 04 December 2018).

67 Garges HP, Alexander KA. Pharmacology review: newer antibiotics: Imipenem/cilastatin and meropenem. NeoReviews. 2003;4(12):364e–8 (, accessed 3 June 2020).

68 Hornik CP, Herring AH, Benjamin DK, Capparelli EV, Kearns GL, van den Anker J et al. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J. 2013;32(7):748–53 (–201307000–00014, accessed 04 January 2019).

69 Dauby N, Muylle I, Mouchet F, Sergysels R, Payen M-C. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr Infect Dis J. 2011;30(9):812–3 ( crossref?an=00006454–201109000–00026, accessed 04 December 2018).

70 De Lorenzo S, Alffenaar JW, Sotgiu G, Centis R, D’Ambrosio L, Tiberi S et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J. 2013;41(6):1386–92.

71 Payen MC MI, Vandenberg O, Mathys V, Delforge M, Van den Wijngaert S, Clumeck N, De Wit S. . Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases. Int J Tuberc Lung Dis. 2018;1(22(1)):34–9.

72 Kuaban C, Noeske J, Rieder HL, Aït-Khaled N, Abena Foe JL, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis. 2015;19(5):517–24.

73 Information for healthcare professionals: gatifloxacin (marketed as Tequin) [website]. US Food and Drug Administration; 2006 ( PostmarketDrugSafetyInformationforPatientsandProviders/ucm107821.htm, accessed 20 March 2020).

74 Trébucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. Int J Tuberc Lung Dis. 2018;22(1):17–25.

75 Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLOS Med. 2018;15(7):e1002591.

76 Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2008;12(2):139–45.

77 Dooley KE, Miyahara S, von Groote-Bidlingmaier F, Sun X, Hafner R, Rosenkranz SL et al.; on behalf of the AIDS Clinical Trials Group A5312 Study Team. Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial. Am J Respir Crit Care Med. 2020;201(11):1416-1424.

78 Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK et al. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020.

79 Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox H, Holtz TH et al. Resistance to fluoroquinolones and secondline injectable drugs: impact on MDR-TB outcomes. Eur Respir J. 2013;42(1):156–68.

80 Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2010;51(1):6– 14 (, accessed 10 April 2020).

81 Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368(9547):1575–80 (, accessed 10 April 2020).

82 Leung ECC, Leung CC, Kam KM, Yew WW, Chang KC, Leung WM et al. Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in a metropolitan city. Eur Respir J. 2013;41(4):901–8 (https://, accessed 30 March 2017).

83 Shah NS, Auld SC, Brust JCM, Mathema B, Ismail N, Moodley P et al. Transmission of extensively drug-resistant tuberculosis in South Africa. New Eng J Med. 2017;376(3):243–53 ( NEJMoa1604544, accessed 30 March 2017).

84 Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD et al. Bedaquiline and delamanid combination treatment of 5 patients with pulmonary extensively drug-resistant tuberculosis. Emerg Infect Dis. 2017;23(10):1718–21 (–0834_article, accessed 11 June 2018).

85 Migliori G, Pontali E, Sotgiu G, Centis R, D’Ambrosio L, Tiberi S et al. Combined use of delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis: a systematic review. Int J Mol Sci. 2017;18(2):341 (–0067/18/2/341, accessed 11 August 2017).

86 Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S et al. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infect Dis. 2018;18(5):536–44.

87 Donald PR. The chemotherapy of tuberculous meningitis in children and adults. Tuberculosis. 2010;90(6):375–92.

88 Sun F, Ruan Q, Wang J, Chen S, Jin J, Shao L et al. Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis. Antimicrob Agents Chemother. 2014;58(10):6297–301.

89 Thwaites GE, Bhavnani SM, Chau TTH, Hammel JP, Torok ME, Van Wart SA et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother. 2011;55(7):3244–53 (, accessed 10 April 2020).

90 Curry International Tuberculosis Center, California Department of Public Health. Drug-resistant tuberculosis: a survival guide for clinicians. California: University of California San Francisco; 2016 (https://www.currytbcenter., accessed 10 April 2020).

91 Daley CL. Mycobacterium tuberculosis complex. In: Yu V, Merigan TJ & Barriere S (eds.), Antimicrobial Therapy and Vaccines, Williams & Wilkins. 1999:531–6.

92 Holdiness MR. Cerebrospinal fluid pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet. 1985;10(6):532–4.

93 Loveday M, Hughes J, Sunkari B, Master I, Hlangu S, Reddy T et al. Maternal and infant outcomes among pregnant women treated for multidrug/rifampicin-resistant tuberculosis in South Africa. Clin Infect Dis. 2020;Published online 6 March 2020.

94 Mitnick CD, White RA, Lu C, Rodriguez CA, Bayona J, Becerra MC et al. Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. Eur Respir J. 2016;48(4):1160–70.

95 Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM et al. Treatment of highly drug-resistant pulmonary tuberculosis. New Eng J Med. 2020;382(10):893–902.

96 Drug approval package: Pretomanid [website]. Maryland, United States of America: US Food and Drug Administration; 2019 ( cfm, accessed 28 February 2020).

97 Pretomanid FGK [website]. Amsterdam, The Netherlands: European Medicines Agency; 2020 (, accessed 5 May 2020).

98 Fox GJ, Mitnick CD, Benedetti A, Chan ED, Becerra M, Chiang C-Y et al. Surgery as an adjunctive treatment for multidrug-resistant tuberculosis:an individual patient data metaanalysis. Clin Infect Dis. 2016;62(7):887–95.

99 Kang MW KH, Choi YS, Kim K, Shim YM, Koh WJ, Kim J. Surgical treatment for multidrug-resistant and extensive drug-resistant tuberculosis. Ann Thorac Surg. 2010;89(5):1597–602.

100 Harris RC, Khan MS, Martin LJ, Allen V, Moore DAJ, Fielding K et al. The effect of surgery on the outcome of treatment for multidrug-resistant tuberculosis: a systematic review and meta-analysis. BMC Infect Dis. 2016;16(1)(–016–1585–0, accessed 12 June 2016).

101 Chotmongkol V, Jitpimolmard S, Thavornpitak Y. Corticosteroid in tuberculous meningitis. J Med Assoc Thai. 1996;79(2):83–90.

102 Kumarvelu S, Prasad K, Khosla A, Behari M, Ahuja GK. Randomized controlled trial of dexamethasone in tuberculous meningitis. Tubercle Lung Dis. 1994;75(3):203–7.

103 Malhotra HS, Garg RK, Singh MK, Agarwal A, Verma R. Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with tuberculous meningitis. Ann Trop Med Parasit. 2009;103(7):625–34.

104 Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics. 1997;99(2):226–31.

105 Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TTO, Nguyen TCT et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. New Eng J Med. 2004;351(17):1741–51.

106 Critchley JA, Young F, Orton L, Garner P. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):223–37.

107 Hakim JG, Ternouth I, Mushangi E, Siziya S, Robertson V, Malin A. Double blind randomised placebo controlled trial of adjunctive prednisolone in the treatment of effusive tuberculous pericarditis in HIV seropositive patients. Heart (British Cardiac Society). 2000;84(2):183–8.

108 Mayosi BM, Ntsekhe M, Bosch J, Pandie S, Jung H, Gumedze F et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. New Eng J Med. 2014;371(12):1121–30 ( doi/full/10.1056/NEJMoa1407380#t=article, accessed 06 July 2017).

109 Mayosi BM, Ntsekhe M, Volmink JA, Commerford PJ. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev 2002;(4):CD000526.

110 Reuter H, Burgess LJ, Louw VJ, Doubell AF. Experience with adjunctive corticosteroids in managing tuberculous pericarditis. Cardiovasc J S Afr. 2006;17(5):233–8.

111 Schrire V. Experience with pericarditis at Groote Schuur Hospital, Cape Town: an analysis of one hundred and sixty cases studied over a six-year period. S Afr Med J. 1959;33:810–7.

112 Strang JI, Kakaza HH, Gibson DG, Allen BW, Mitchison DA, Evans DJ et al. Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet. 1988;2(8614):759–64.

113 Strang JI, Kakaza HH, Gibson DG, Girling DJ, Nunn AJ, Fox W. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet. 1987;2(8573):1418–22.

114 Report of the expert consultation on immunotherapeutic interventions for tuberculosis (TDR/IRM/07.1). Geneva, Tropical Disease Research:2007 ( pdf, accessed 10 April 2020).

115 Skrahin A, Ahmed RK, Ferrara G, Rane L, Poiret T, Isaikina Y et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med. 2014;2(2):108–22.

116 Skrahin A, Jenkins HE, Hurevich H, Solodovnikova V, Isaikina Y, Klimuk D et al. Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis. J Clin Tuberc Other Mycobact Dis. 2016;4:21–7 (https://, accessed 04 July 2017).

117 Koh WJ, Kwon OJ, Suh GY, Chung MP, Kim H, Lee NY. Six-month therapy with aerosolized interferon-γ for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci. 2004;19(2):167–71.

118 Park SK, Cho S, Lee IH, Jeon DS, Hong SH, Smego RA. Subcutaneously administered interferon-gamma for the treatment of multidrug-resistant pulmonary tuberculosis. Int J Infect Dis. 2007;11(5):434–40.

119 Suárez-Méndez R, García-García I, Fernández-Olivera N, Valdés-Quintana M, Milanés-Virelles MT, Carbonell D et al. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis. 2004;4(1)(–2334–4-44, accessed 18 June 2018).

120 Yang Z, Wang L, Guo L, Lin M, Chen X. A short term efficacy of aerosolising inhalation recombinant human gamma interferon in multidrug resistant pulmonary tuberculosis. Journal of the Chinese Anti-Tuberculosis Association. 2009;3(11):600–3.

121 Wallis RS. Lack of a therapeutic role for interferon γ in patients with tuberculosis. Int J Infect Dis. 2014;209(4):627–8.

122 Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E et al. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS medicine. 2018;15(7):e1002595.

123 Ho J, Byrne AL, Linh NN, Jaramillo E, Fox GJ. Decentralized care for multidrug-resistant tuberculosis: a systematic review and meta-analysis. Bull World Health Organ. 2017;95(8):584–93.

124 Cocozza A, Linh N, Jaramillo E. Is effective patient support missing in the global response to multidrugresistant tuberculosis? Int J Tuberc Lung Dis. 2020;24(6).

125 Delivering comprehensive supportive care to people with drug-resistant tuberculosis. Washington, DC: United States Agency for International Development; 2019 (, accessed 1 June 2020).

126 Campbell J, Falzon D, Mirzayev F, Jaramillo E, Migliori G, Mitnick C et al. Improving quality of patient data for treatment of multidrug- or rifampin-resistant tuberculosis. Emerg Infect Dis. 2020;26(3).

127 World Health Organization, Management Sciences for Health, KNCV Tuberculosis Foundation. Electronic recording and reporting for tuberculosis care and control (WHO/HTM/TB/2011.22). Geneva: World Health Organization; 2012 (, accessed 20 March 2020).

128 International standards for tuberculosis care. 3rd edition [website]. The Hague: TB CARE 1; (https://www., accessed 22 March 2020).

Book navigation